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Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in
the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness
Analysis of eHealth Tools to Support All Stages of Screening
Abstract
BACKGROUND Internationally, most atrial fibrillation (AF) management guidelines recommend
opportunistic screening for AF in people ≥65 years of age and oral anticoagulant treatment for those at
high stroke risk (CHA₂DS₂-VA≥2). However, gaps remain in screening and treatment. METHODS AND
RESULTS General practitioners/nurses at practices in rural Australia (n=8) screened eligible patients (≥65
years of age without AF) using a smartphone ECG during practice visits. eHealth tools included electronic
prompts, guideline-based electronic decision support, and regular data reports. Clinical audit tools
extracted de-identified data. Results were compared with an earlier study in metropolitan practices (n=8)
and nonrandomized control practices (n=69). Cost-effectiveness analysis compared population-based
screening with no screening and included screening, treatment, and hospitalization costs for stroke and
serious bleeding events. Patients (n=3103, 34%) were screened (mean age, 75.1±6.8 years; 47% men) and
36 (1.2%) new AF cases were confirmed (mean age, 77.0 years; 64% men; mean CHA₂DS₂-VA, 3.2). Oral
anticoagulant treatment rates for patients with CHA₂DS₂-VA≥2 were 82% (screen detected) versus 74%
(preexisting AF)(P=NS), similar to metropolitan and nonrandomized control practices. The incremental
cost-effectiveness ratio for population-based screening was AU$16 578 per quality-adjusted life year
gained and AU$84 383 per stroke prevented compared with no screening. National implementation would
prevent 147 strokes per year. Increasing the proportion screened to 75% would prevent 177 additional
strokes per year. CONCLUSIONS An AF screening program in rural practices, supported by eHealth tools,
screened 34% of eligible patients and was cost-effective. Oral anticoagulant treatment rates were
relatively high at baseline, trending upward during the study. Increasing the proportion screened would
prevent many more strokes with minimal incremental cost-effectiveness ratio change. eHealth tools,
including data reports, may be a valuable addition to future programs. REGISTRATION URL:
https://www.anzctr.org.au. Unique identifier: ACTRN12618000004268.
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and Guideline-Recommended Therapy in
the Rural Primary Care Setting: A CrossSectional Study and Cost-Effectiveness
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BACKGROUND: Internationally, most atrial fibrillation (AF) management guidelines recommend opportunistic screening for AF in
people ≥65 years of age and oral anticoagulant treatment for those at high stroke risk (CHA₂DS₂-VA≥2). However, gaps remain
in screening and treatment.
Downloaded from http://ahajournals.org by on September 29, 2020

METHODS AND RESULTS: General practitioners/nurses at practices in rural Australia (n=8) screened eligible patients (≥65 years
of age without AF) using a smartphone ECG during practice visits. eHealth tools included electronic prompts, guideline-based
electronic decision support, and regular data reports. Clinical audit tools extracted de-identified data. Results were compared with an earlier study in metropolitan practices (n=8) and nonrandomized control practices (n=69). Cost-effectiveness
analysis compared population-based screening with no screening and included screening, treatment, and hospitalization
costs for stroke and serious bleeding events. Patients (n=3103, 34%) were screened (mean age, 75.1±6.8 years; 47% men)
and 36 (1.2%) new AF cases were confirmed (mean age, 77.0 years; 64% men; mean CHA₂DS₂-VA, 3.2). Oral anticoagulant
treatment rates for patients with CHA₂DS₂-VA≥2 were 82% (screen detected) versus 74% (preexisting AF)(P=NS), similar to
metropolitan and nonrandomized control practices. The incremental cost-effectiveness ratio for population-based screening was AU$16 578 per quality-adjusted life year gained and AU$84 383 per stroke prevented compared with no screening.
National implementation would prevent 147 strokes per year. Increasing the proportion screened to 75% would prevent 177
additional strokes per year.
CONCLUSIONS: An AF screening program in rural practices, supported by eHealth tools, screened 34% of eligible patients
and was cost-effective. Oral anticoagulant treatment rates were relatively high at baseline, trending upward during the study.
Increasing the proportion screened would prevent many more strokes with minimal incremental cost-effectiveness ratio
change. eHealth tools, including data reports, may be a valuable addition to future programs.
REGISTRATION: URL: https://www.anzctr.org.au. Unique identifier: ACTRN12618000004268.
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CLINICAL PERSPECTIVE
What Is New?

• This study extends the evidence base in rural
areas by demonstrating that a screening program using eHealth tools in a rural general
practice setting can successfully screen 34% of
eligible patients with atrial fibrillation with guideline-indicated treatment rates >80% for screendetected atrial fibrillation cases.
• Economic modeling showed that the program
was cost-effective compared with no screening.
• Oral anticoagulant treatment rates for eligible
patients were higher than previous studies at
baseline (>70%) and were trending upward during the study (around 80%).

What Are the Clinical Implications?

• eHealth tools, particularly customized data reports
as part of an audit and feedback system, may be a
valuable addition to screening programs.
• Half of the practices screened 40% to 50% of
eligible patients, suggesting that this may represent a ceiling of patients captured by opportunistic atrial fibrillation screening programs in the
general practice setting.
• Increasing the proportion screened would prevent many more strokes with minimal change to
the incremental cost-effectiveness ratio.
Downloaded from http://ahajournals.org by on September 29, 2020

Nonstandard Abbreviations and Acronyms
AF
EDS
GP
iECG
ICER
NOAC
OAC
QALY
QI

I

atrial fibrillation
electronic decision support
general practitioner
handheld single-lead smartphone ECG
incremental cost-effectiveness ratio
non–vitamin K dependent oral
anticoagulant
oral anticoagulant
quality-adjusted life year
quality improvement

nternationally, opportunistic screening for atrial fibrillation (AF) in people ≥65 years of age is now recommended by most guidelines.1,2 Single timepoint
screening detects undiagnosed AF, which is often
asymptomatic, in approximately 1.4% of people in this
age group.3 Guidelines generally recommend treatment with oral anticoagulants (OACs),1,2 which can reduce the risk of AF-related stroke by 64% for those at
high risk (“sexless” CHA₂DS₂-VA [C = congestive heart

failure/left ventricular dysfunction, H = high blood pressure, A2 = 75 years of age and older, D = diabetes
mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease (coronary artery disease, myocardial infarction, peripheral artery disease,
aortic plaque), A = 65–74 years of age] risk score≥2).4
Large gaps in screening and treatment exist in
practice. A survey conducted by The Economist in
2017 reported that only 11% of people ≥65 years of
age were screened in Australian general practices in
the previous fortnight.5 Our previous 2018 study using
eHealth tools conducted in metropolitan general practices increased screening to 16% of eligible patients.6
In terms of treatment, rates have historically been 50%
to 60%. However, since non–vitamin K dependent
OAC (NOAC) medicines were introduced, an increase
in treatment rates has been reported in Europe (>77%
in England7 and >65% in Denmark8). This trend was
also reflected in our 2018 metropolitan study, which
reported a treatment rate of 71% for those diagnosed
with AF before the study, increasing to >80% for those
diagnosed during the study period.6
Australians living in rural areas have more limited
access to health services and worse cardiovascular
outcomes.9 The ratios of general practitioners (GPs),
specialists, and nurses per capita of population are significantly lower in rural areas than in metropolitan areas,
and access to specialist cardiac care is more limited.10,11
Approximately 25% of the rural population suffers from
cardiovascular diseases compared with 20% in metropolitan areas, and the likelihood of hospitalization and
death resulting from cardiac events increases with the
distance from metropolitan areas.12 General practices
play a key role in supporting cardiac health in rural areas
as they tend to provide a broader range of community
services compared with metropolitan practices.13
Several of our previous studies showed that opportunistic screening in primary care by GPs and nurses
was feasible.6,14,15 A suite of customized eHealth tools,
including an automated prompt and electronic decision support (EDS), were found to be promising.6
These tools have been refined and enhanced with a
quality improvement (QI) focus16,17 and are designed to
support all stages of screening.
This study aims to improve the proportion of patients screened and treated for AF using the refined
eHealth tools and to inform strategies on AF screening implementation in the rural setting. In addition, this
study provides the first cost-effectiveness analysis in
Australian general practice.

METHODS
This study was conducted in a convenience sample of
8 rural general practices from September 2018 to July
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2019 in rural New South Wales, Australia. Practices
were required to be located outside a major city
(generally categorized under the Australian Statistical
Geography Standard–Remoteness Area 201618 code
2 “inner regional Australia”) and were recruited by
advertisements in primary health network newsletters and by word of mouth. Participating practices
provided written informed consent, and patients provided oral consent for screening. This study was approved by the University of Sydney Human Research
Ethics Committee (Project No. 2017/1017; Clinical
Trial Registration No. ACTRN12618000004268). The
data and materials will not be made available to other
researchers as data sharing is not permitted by our
ethics committee approval. Researchers interested in
the data, methods, or analysis can contact the corresponding author for more information.
The methods for this study have been previously described in detail.17 Briefly, GPs and/or practice nurses
offered screening for AF with smartphone handheld
single-lead ECGs (iECGs) (KardiaMobile) to eligible
patients attending the practice for any reason. Eligible
patients were those ≥65 years of age without an existing AF diagnosis who had not already been screened
with the iECG within the past 12 months. All follow-up
for those with abnormal screening results according
to the iECG app (“possible AF” or “unclassified”) and
treatment decisions were at the discretion of the GP.
To support screening, practices were provided with
eHealth tools (Figure 1).
• Screening prompt: An app located in a third-party
hosting platform automatically extracted information
from patients’ electronic medical records. Using this
information in real time, a prompt appeared when
an eligible patient’s file was opened. The iECG automated screening result was also recorded in this app.

AF SMART II: AF Screening in Rural Primary Care

• EDS: For those diagnosed with AF (either by screening or otherwise), the EDS app (also located on
the third-party hosting platform) calculated their
CHA₂DS₂-VA stroke risk score and made guideline
recommendations regarding treatment. This app
was part of the HealthTracker suite of cardiovascular
QI tools.
• Tailored clinical audit data for QI reporting:
Customized, de-identified clinical audit data extracts
were obtained monthly from participating practices.
These data were used to report back to practices
and included data on the number and proportion
screened, the number of patients with new AF, and
the proportion treated according to guidelines.

Reimbursement
Practices were paid $1000 to cover study setup time
and data extraction costs plus $10 per patient screened
(paid per 100 patients to encourage greater numbers).
This was intended to cover the costs of screening in
the Australian fee-for-service context and to replicate
a real-world fee if screening was covered by Medicare.
Screening was free for patients, although any usual
consultation fees applied.

Data Collection and Analysis
De-identified data extracts included demographic,
iECG screening, medication, and diagnostic information from the practices’ electronic patient records. The
data extracts were designed to collect data for all active patients of the practices, that is, patients who had
attended at least 3 times in the past 2 years and once
in the past 6 months.
To provide additional context about broader
screening and treatment trends, data from this study
were compared with 2 other de-identified data sets:

Figure 1. Screening process and eHealth tools adapted from our 2018 metropolitan study.6
AF indicates atrial fibrillation; QI, quality improvement.
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the metropolitan group and the nonrandomized
control group. These comparator data sets were
collected from other Australian studies also using
the HealthTracker app, with prospectively collected
data using the same data extraction tool and data
fields. The metropolitan group was from our 2018
AF screening study,6 which included 8 metropolitan
general practices. The nonrandomized control group
was composed of 69 practices (64 metropolitan and
5 rural) that were using HealthTracker for general cardiovascular QI studies that did not involve AF screening. For the purposes of comparisons of treatment
rates before and during the study period, the nonrandomized control group data were split into AF diagnoses before January 1, 2018 (baseline treatment
rate) and AF diagnosed on or later than January 1,
2018 (AF diagnosed during the study period).
Descriptive analyses for the rural practices were
carried out using Microsoft Excel. Descriptive analyses of nonrandomized control data were performed
using R Statistical Programming, version 3.6.1.19
Comparisons of treatment rates between groups
were calculated using the Fisher exact test (2-sided
P values) performed using 2×2 contingency tables
(GraphPad Prism version 7.04) with significance set a
priori at P<0.05. Although our protocol paper specified
a chi-square test, the Fisher exact test was used as it
was more accurate with the small numbers involved.
A detailed process evaluation was carried out using
mixed methods, including semistructured interviews
with selected practice staff. This evaluation examined
outcomes related to implementation success and the
acceptability/competing demands of the screening
program. Methods and results of this evaluation have
been described elsewhere.16

Cost-Effectiveness Analysis
The iECG screening program was evaluated by
comparing population-based AF screening with
no screening from an Australian health funder perspective. The economic model developed in the
SEARCH-AF (Screening Education and Recognition
in Community Pharmacies of Atrial Fibrillation)20
pharmacy screening study was adapted to evaluate iECG screening in general practice. The model
has previously been explained in detail.20 Briefly, the
model compares the cost of iECG screening, diagnosis, and treatment in general practice to diagnosed
AF in the unscreened population of Australian men
and women 65 to 84 years of age. That is, it compares population-based AF screening to no screening. It assumes a base rate of AF (both diagnosed
and unknown) and follows a cohort of the population
65 to 84 years of age for 10 years with annual stroke
events and all-cause mortality.

AF SMART II: AF Screening in Rural Primary Care

Stroke costs included hospitalization, rehabilitation,
and other ongoing medical costs. For this study, the
model was updated to include the cost of an echocardiogram for those diagnosed and the costs of major
bleeding episodes for those on OAC treatment and a
treatment regimen consistent with current trends (that
is, including NOACs prescribed at rates observed in
the current study).
The model included several key assumptions (full
list included as Table S1).
• The proportion screened was that observed in this
study.
• The prevalence of diagnosed AF in the population
≥65 years of age was 4.4%.3
• The prevalence of unknown AF in the population ≥65
years of age was 1.4%.3
• OAC and antiplatelet treatment rates were as
observed for all patients diagnosed during the
study period (both screen detected and otherwise
detected).
• The iECG test sensitivity was 97%, and specificity
was 92%.
• The cost per screen was $20.
• For those diagnosed with AF, annual treatment and
monitoring costs for those on OACs were $1063.78
(warfarin) and $1401.73 (mean cost for NOACs) and
included annual costs of medication, pathology, GP,
and specialist visits.
Costs for hospitalization for stroke were obtained
from Cadilhac et al21 and were updated to 2019 prices
using the Australian Health Price Deflator Index. In addition, a present value of 5.09 quality-adjusted life years
(QALYs) (gained over a lifetime) was used for each ischemic stroke prevented by screening.21
Results are presented in Australian dollars as an
incremental cost-effectiveness ratio (ICER) per stroke
avoided and per QALY gained for population-based
screening compared with no screening. Sensitivity
analyses were also performed for different proportions
of patients screened, price reductions in NOAC medicines, differences in iECG test sensitivity and specificity, differences in OAC treatment rates, and differences
in rates of major bleeding episodes.

Outcomes
Key study outcomes were the following:17
• the proportion of screened patients with confirmed
new AF,
• the proportion of AF and screened patients where
the EDS was accessed,
• the proportion of patients with AF diagnosed during
the study period in the OAC recommended category
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(CHA₂DS₂-VA risk score≥2)1 who were prescribed an
OAC according to guidelines,
• baseline AF prevalence in patients ≥65 years of age
compared with metropolitan and nonrandomized
control groups,
• new screen-detected AF incidence at the end of the
study period in patients ≥65 years of age compared
with the metropolitan and nonrandomized control
groups, and
• rates of OAC and antiplatelet treatment at baseline
and completion for patients in the OAC recommended category compared with the metropolitan
and nonrandomized control groups.

RESULTS

AF SMART II: AF Screening in Rural Primary Care

AF Prevalence and Treatment Rates
Compared With Metropolitan and
Nonrandomized Control Groups
The baseline prevalence of AF in the rural and metropolitan practices and nonrandomized control groups
ranged from 9% to 12% (Table 2).
There were no significant differences between
the rural and metropolitan practices’ treatment rates
of those with AF detected before the study or during
the study (screen-detected and otherwise-detected)
(Table 2). Likewise, the treatment rates in the rural
practices were similar to those in the nonrandomized
control practices at baseline and during the study period (Table 2). The OAC treatment rates in all 3 cohorts
tended to increase from baseline (Table 2), in contrast
to antiplatelets.

Downloaded from http://ahajournals.org by on September 29, 2020

Screening, Diagnosis, and Treatment

Cost-Effectiveness Analysis

A total of 8 general practices were recruited and
screened a total of 3103 eligible patients (mean age,
75.1±6.8 years; 47% men) during the study period.
The median screening period was 4.6 months (range,
1.7–7.5 months). Practices screened a mean of 34%
(median 35%) of eligible patients (range, 9%–51% per
practice), with 4 of 8 practices screening >40% of eligible patients (Figure 2). In general, screening was highest in the first 1 to 2 months and declined thereafter.
The mean proportion of all eligible patients who attended the practices during the study period was 94%.
GPs (n=22) screened 31% (range, 1–182 per GP) of patients and nurses (n=40) screened 69% (range, 1–192
per nurse). According to the iECG automated algorithm (as entered into the app by GPs/nurses), 83% of
screenings were normal, 13% were unclassified, and
4% were possible AF.
In total, 36 (1.2%) of new cases of screen-detected
AF were confirmed (mean age, 77.0 years; 64% men;
mean CHA₂DS₂-VA, 3.2) (Table 1). The proportion of
screen-detected patients with AF with at least 1 nonage or sex risk factor was 83%, and the proportion
in the OAC recommended category (CHA₂DS₂-VA≥2)
was 94%. Characteristics and CHA₂DS₂-VA groups for
those with screen-detected AF, otherwise-detected AF
(during the study period), and AF detected before the
study are presented in Table 1.
OAC treatment rates of patients with AF with
CHA₂DS₂-VA≥2 were 82% (screen-detected), 75%
(otherwise-detected during study period), and 74%
(preexisting AF), with no significant differences between treatment rates in the screen-detected group
and other groups (Table 1). The EDS was accessed
for 54 of 1337 (4%) patients 65 years of age and older
with AF and for 4 of 36 (11%) patients with new screendetected AF.

Our cost-effectiveness modeling showed that for
population-based AF screening for Australian men
and women 65 to 84 years of age, assuming a 34%
screening participation rate with a treatment rate of
82% in the screened population and a test sensitivity of
97% and specificity of 92%, the ICER per QALY gained
was AU$16 578 and the ICER per stroke avoided was
≥≥84 383 compared with no screening.
Increasing the screening participation rate has a
negligible effect on the ICER, but substantially increases the number of strokes prevented, that is,
effectiveness (Table 3). Increasing the screening participation rate from 34% to 50% raises the number
of strokes prevented from the base case of 147 per
year to 216 per year (or 1467 to 2157 over 10 years).
With a 75% screening participation rate, a total of
324 strokes are prevented each year (or 3235 strokes
over 10 years) when compared with the no screening
scenario.
Raising the OAC treatment rate also prevents more
strokes, with a relatively small impact on the ICER. An
OAC treatment rate of 90% (in both the screened and
unscreened populations) would prevent a total of 1610
strokes over 10 years, with an ICER per QALY gained
of $16 188 compared with no screening.
For population-based screening, lowering the
cost of NOAC treatment decreases the ICER per
QALY gained to AU$14 997 (12.5% price reduction) or
AU$13 416 (25% price reduction) compared with no
screening.
Furthermore, changes to the iECG test sensitivity
and specificity did not have material impacts on the
ICER per stroke prevented nor the ICER per QALY
gained compared with no screening. However, increasing the test sensitivity to 100% did prevent an additional
45 strokes over 10 years. Similarly, sensitivity analyses
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Figure 2. Screening flowchart.
*Unclassified results may be attributed to sinus bradycardia, sinus tachycardia, left or right bundle
branch block, multiple ectopic beats, or other arrythmias. AF indicates atrial fibrillation; CHA₂DS₂-VA, C
= congestive heart failure/left ventricular dysfunction, H = high blood pressure, A 2 = 75 years of age and
older, D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease
(coronary artery disease, myocardial infarction, peripheral artery disease, aortic plaque), A = 65 to 74 years
of age; GP, general practitioner; iECG, handheld single-lead smartphone ECG; and OAC, oral anticoagulant.

regarding major bleeding rates did not have a material
impact on the ICER per stroke prevented nor the ICER
per QALY gained compared with no screening.

DISCUSSION
This study investigated the impact of an AF screening
program in rural general practices using an iECG together

with a suite of custom-designed eHealth tools designed
to increase the proportion screened and treated for AF
in accordance with guidelines. GPs and nurses at participating practices screened a total of 3103 eligible patients, and 36 (1.2%) new cases of AF were confirmed,
with 82% prescribed OAC according to guidelines.
This study featured a unique suite of integrated,
customized eHealth tools to support all stages of AF
screening and treatment in general practice. These
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Table 1. Characteristics and Stroke Risk of Those ≥65 Years of Age With AF
Screen-Detected AF

Otherwise-Detected AF
During Study Period

Baseline: AF Diagnosed
Before Study

(n=36)

(n=58)

(n=1243)

77.0±6.1

77.0±8.4

79.2±7.8

23 (64)

32 (55)

662 (53)

3.2

3.3

3.7

CHA₂DS₂-VA≥2, n (% of total)

34 (94)

55 (95)

1223 (98)

CHA₂DS₂-VA≥2 and prescribed OACs, n (% of those with
CHA₂DS₂-VA≥2)

28 (82)

41 (75) P=0.444*

908 (74) P=0.326*

≥1 nonage or sex risk factors, n (% of total)

30 (83)

54 (93)

1178 (95)

Age, y, mean±SD
Male, n (%)
Mean CHA₂DS₂-VA

AF indicates atrial fibrillation; and CHA₂DS₂-VA, C = congestive heart failure/left ventricular dysfunction, H = high blood pressure, A 2 = 75 years of age and
older, D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease (coronary artery disease, myocardial infarction,
peripheral artery disease, aortic plaque), A = 65 to 74 years of age; and OAC, oral anticoagulant.
*P value for comparison to screen-detected AF.
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tools were refined following our metropolitan study6
and included an automated screening prompt (with
improved visibility and reliability), an EDS app to guide
treatment, and de-identified data extracts and with
regular QI audit and feedback reporting to practices.
We are not aware of any other studies that include
tools to cover all stages of AF screening and treatment,
including customized feedback. In particular, the refined screening prompt and the improved QI reporting
were useful and motivating for participating GPs and
nurses.16

Proportion Screened and Treated
Practices screened 34% of eligible patients who attended during the study period, which is substantially
higher than the 16% achieved in our metropolitan study.6
Half of the study practices were able to screen >40%
of eligible patients, although 51% was the maximum
reached. It appeared that even practices with broad
uptake and high motivation across staff were not able
to capture more than 50% of eligible patients, which
GPs and nurses indicated was largely attributed to time
constraints and technical issues (eg, difficulty taking a

Table 2. Treatment Rates and Comparisons Between Groups: Patients ≥65 Years of Age With AF
Rural Practices
(n=8)

Metropolitan Practices
(n=8)

Nonrandomized Control Practices
(n=69)

10 896

13 679

30 116

12%

11%

9%

Total active* patients ≥65 years of age
Baseline AF prevalence
Baseline: AF detected before study with CHA 2DS₂-VA≥2
Total, n

1223

1306

1875

Prescribed OAC, n (%)

908 (74)

933 (71) P=0.118†

1450 (77) P=0.052†

Prescribed antiplatelet alone, n (%)

178 (15)

213 (16)

248 (13)

Not prescribed OAC or antiplatelet, n (%)

137 (11)

160 (12)

177 (9)

Screen-detected AF during study period with CHA₂DS₂-VA≥2
Total, n

34

18

N/A

28 (82)

15 (83) P>0.999†

N/A

Prescribed antiplatelet alone, n (%)

1 (3)

1 (6)

N/A

Not prescribed OAC or antiplatelet, n (%)

5 (15)

2 (11)

N/A

Prescribed OAC, n (%)

All AF detected during study period (screen detected+otherwise detected) with CHA₂DS₂-VA≥2
Total, n
Prescribed OAC, n (%)
Prescribed antiplatelet alone, n (%)
Not prescribed OAC or antiplatelet, n (%)

89

64

399

69 (78)

54 (84) P=0.312†

333 (83) P=0.218†

7 (8)

3 (5)

29 (7)

13 (15)

7 (11)

37 (9)

AF indicates atrial fibrillation; CHA₂DS₂-VA, C = congestive heart failure/left ventricular dysfunction, H = high blood pressure, A 2 = 75 years of age and older,
D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease (coronary artery disease, myocardial infarction, peripheral
artery disease, aortic plaque), A = 65 to 74 years of age; and OAC, oral anticoagulant.
*Active patients are those who attended the practice at least 3 times in the past 2 years and once in the past 6 months.
†
P value for comparison to rural practices.
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Table 3. Cost-Effectiveness of Population-Based AF Screening Compared With No Screening and Sensitivity Analyses
Over 10 Years
Base Case
Screening participation rate, %

34

50

60

70

75

1467

2157

2588

3020

3235

Net cost [ICER] per stroke prevented compared with
no screening

$84 383

$83 304

$82 922

$82 649

$82 540

Net cost [ICER] per QALY gained compared with no
screening

$16 578

$16 366

$16 291

$16 238

$16 216

Number of strokes prevented

NOAC price reduction

-

12.5%

25%

1467

1467

1467

Net cost [ICER] per stroke prevented compared with
no screening

$84 383

$76 336

$68 289

Net cost [ICER] per QALY gained compared with no
screening

$16 578

$14 997

$13 416
100%

Number of strokes prevented

iECG test sensitivity

97%

92%

1467

1391

1512

Net cost [ICER] per stroke prevented compared with
no screening

$84 383

$85 940

$83 524

Net cost [ICER] per QALY gained compared with no
screening

$16 578

$16 884

$16 409

Number of strokes prevented

iECG test specificity

92%

89%

93%

1467

1467

1467

Net cost [ICER] per stroke prevented compared with
no screening

$84 383

$86 818

$83 571

Net cost [ICER] per QALY gained compared with no
screening

$16 578

$17 057

$16 419

74%*/82%†

55%

90%

1467

984

1610

Net cost [ICER] per stroke prevented compared with
no screening

$84 383

$97 731

$82 397

Net cost [ICER] per QALY gained compared with no
screening

$16 578

$19 201

$16 188

4.8

2.2

7.4

Number of strokes prevented

OAC treatment rate
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Number of strokes prevented

Major bleeds–crude excess incidence rate per 1000
person-years of major bleeds for those 65–74 years of
age
Number of strokes prevented

1467

1467

1467

Net cost [ICER] per stroke prevented compared with
no screening

$84 383

$83 409

$85 358

Net cost [ICER] per QALY gained compared with no
screening

$16 578

$16 387

$16 770

4.2

1.3

7.2

Major bleeds–crude excess incidence rate per 1000
person-years of major bleeds for those 75–84 years of
age
Number of strokes prevented

1467

1467

1467

Net cost [ICER] per stroke prevented compared with
no screening

$84 383

$83 753

$85 035

Net cost [ICER] per QALY gained compared with no
screening

$16 578

$16 454

$16 706

AF indicates atrial fibrillation; ICER, incremental cost effectiveness ratio; QALY, quality-adjusted life year; NOAC, non-vitamin K dependent anticoagulant;
OAC, oral anticoagulant; and $ = Australian dollars (AUD).
*Unscreened population.
†
Screened population.

reading on some patients).16 Key features of the most
successful practices included leadership from a senior
GP “screening champion,” clear protocols for followup of abnormal results for nurse-led screening, and

sufficient staff time allocation for screening. These are
discussed in detail in our qualitative realist evaluation.16
A recent study of AF screening in 184 Canadian
practices was able to screen 42% of eligible
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Figure 3. Summary of findings.
AF indicates atrial fibrillation; CHA₂DS₂-VA, C = congestive heart failure/left ventricular dysfunction, H = high blood pressure, A 2 = 75
years of age and older, D = diabetes mellitus, S2 = stroke/transient ischemic attack/thromboembolism, V = vascular disease (coronary
artery disease, myocardial infarction, peripheral artery disease, aortic plaque), A = 65 to 74 years of age; and OAC, oral anticoagulant.
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patients.22 In addition, a study from the Netherlands
where patients ≥65 years of age were screened in 10
general practices during influenza vaccination sessions captured 35% of eligible patients, which is almost identical to our study.23 These results suggest
that 40% to 50% may be a “ceiling” of eligible patients captured by an opportunistic screening program in general practice.
As with the metropolitan study, treatment rates
were high at baseline (>70%) compared with historical
Australian data and increased during the study. The
treatment rates were highest for screen-detected AF
(>80%). These treatment rates and trends were similar
to those in the nonrandomized control practices. These
rates are higher than previously reported in Australia,
which were about 55% to 60%24 before the introduction of NOACs (preferred by the Australian guidelines).1
Our results show a similar trend to recent European
treatment rates of around 65% to 80%8,25,26 since the
introduction of NOACs.
Our results also show a decline in antiplatelet prescription for those not on OACs. Of the patients diagnosed during the study period (≥65 years of age
with CHA₂DS₂-VA≥2) who were not prescribed OACs
(n=20), only a minority were prescribed antiplatelets
alone (n=7) with the remainder on no therapy (n=13).
Of the 7 patients prescribed antiplatelets alone, 2 of
these patients were prescribed antiplatelets before
being diagnosed with AF (1 of whom had cardiovascular disease) and another 3 of these patients also
had cardiovascular disease, which may be the reason
antiplatelets were prescribed. This suggests that the
prescription of antiplatelets alone for AF may be declining, as was recently reported in a US study27 and that
effectively the prescribing decision is becoming “OAC
or no treatment.”

Rural Setting
This study extends the evidence base in rural areas
and shows that a screening program in the rural general practice setting can successfully screen a large
number of eligible patients with AF with guideline-indicated treatment rates >80% for screen-detected AF
cases. A screening program using pulse palpation in
rural general practice in Ireland achieved a similar reach
to our study (30% of the general practice population
≥65 years of age screened), although OAC treatment
rates were lower (65%).28 The authors noted important
differences regarding the density of population in rural
studies compared with metropolitan studies, with implications for rural patients’ access to primary and secondary care.
Prevention programs suitable for rural areas are
particularly important given that people living in these
areas tend to have worse cardiovascular outcomes
and less access to specialist medical services.9
Rural general practice is potentially an ideal setting
for implementation of innovative primary care-based
cardiac programs, such as ours, which contribute to
upskilling GPs in cardiac care, training nurses to provide cardiac education/screening, and using novel
technology.

Cost-Effectiveness
Our cost-effectiveness modeling showed that for
population-based AF screening in general practice
for Australian men and women 65 to 84 years of age,
the ICER per QALY gained was AU$16 578 and the
ICER per stroke avoided was AU$84 383 compared
with no screening. Increasing the proportion screened
from 34% to 75% would prevent an additional 177
strokes per year (or 1768 strokes over 10 years) with a
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negligible effect on the ICER. These figures are higher
than for SEARCH-AF,20 largely driven by an increased
uptake of OAC treatment rates and in particular the
higher prescription rates of NOACs. The increased
proportion of people treated with OAC reduces the
ICER, although this is offset by the higher cost of treatment with NOACs. These figures are well within the
accepted thresholds of Australian government health
expenditures.29 This is consistent with several other
studies, which found AF screening to be cost-effective30 or even cost-saving.31
Importantly, although we were able to screen 34%
of eligible people with these tools (and have suggested
that 40%–50% may be a “ceiling” of patients captured
with opportunistic screening programs), these analyses highlight the impact of increasing the proportion
screened in terms of stroke prevention and the need
to consider new approaches to break the 40% to 50%
barrier.

Limitations
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The proportion of non-normal results according to
the iECG device algorithm was relatively high at 17%
(possible AF, 4%; unclassified, 13%). This added to
the workload substantially for practices, as was also
noted in a recent Canadian study,22 as all of these
patients require some degree of follow-up. In relation to the possible AF readings, it is likely that some
were paroxysmal AF (AF not present on a subsequent 12-lead ECG) or false positives (eg, attributed
to sinus arrhythmia, multiple atrial ectopics, or a poor
quality trace). It is also possible that some AF diagnoses were not recorded in the clinical system (see
Limitations below). In relation to the unclassified results, previous studies have usually reported lower
rates closer to 10%.6,14 Improvements in the device
algorithm (eg to identify sinus tachycardia/bradycardia) and training staff in techniques to take clearer
readings will reduce this burden. We note that the
research team was not able to review the iECGs and
relied on GPs/nurses to manually enter the device’s
interpretation into the AF app. The iECG automated
algorithm has been reported to have a sensitivity of
97% and specificity of 92%.20
The EDS was only used for a low proportion of
patients. This is probably because it was in a separate app and was not accessed by GPs as it required extra clicks. Ideally, an EDS would need to be
a more integral part of the electronic medical record
system. Alternatively, an automatic calculation of patients’ CHA₂DS₂-VA scores in the electronic medical
record would assist, particularly if it included an alert
to review treatment when the score changed (especially when it exceeds a treatment-recommendation
threshold).

AF SMART II: AF Screening in Rural Primary Care

The study relied on de-identified data collected
from practices. This was routinely collected general
practice data with all its inherent limitations. For example, if GPs recorded a diagnosis of AF in the free-text
notes section instead of adding it as a condition from
a drop-down list, this would not be caught in our data,
meaning our figures may underestimate the true rate of
AF detected during the study. In addition, these data
were limited to active patients because of the definition in the data collection tool. “Active patients” were
defined as those who had attended the practice at
least 3 times in the past 2 years and once in the past
6 months. Therefore, our data may be biased toward
people with more chronic conditions requiring more
frequent attendance at the practice.
There were some limitations in relation to the
cost-effectiveness analysis. A key methodological limitation is that a probabilistic sensitivity analysis was not
undertaken to show model uncertainty, and therefore
the model only reports point estimates on cost-effectiveness. However, this is consistent with the main purpose of the model, which was to provide an estimate
of the cost-effectiveness and number of strokes prevented if the AF-SMART system was implemented nationally. In addition, the model has not been validated
or calibrated to test whether predicted events are consistent with observed data.

CONCLUSIONS
An AF screening program in rural general practices,
supported by eHealth tools, screened 34% of eligible patients, with 82% of new screen-detected cases
treated according to guideline (Figure 3). Half of the
practices screened 40% to 50% of eligible patients,
suggesting that this may represent a “ceiling” of patients captured by opportunistic AF screening programs. OAC treatment rates were higher than previous
studies at baseline and were trending upward during
the study. Increasing the proportion screened would
prevent many more strokes with minimal changes to
the ICER. This may require new methods to break
through the ceiling captured by numerous opportunistic programs. eHealth tools, particularly customized
data reports as part of an audit and feedback system, may be a valuable addition to future screening
programs.
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Table S1. Cost-effectiveness model assumptions.
Item
Prevalence of known AF in the
population aged 65-84 years
Prevalence of unknown AF in the
population aged 65-84 years
iECG test sensitivity
iECG test specificity
Population

OAC treatment rates (unscreened
population)
OAC treatment rates (screened
population)
OAC treatment (screened and
unscreened): warfarin vs NOACs
Screening participation rate
Cost per screen

Cost/measure
4.4%

Details

1.4%

Lowres et al, 20193

97% (95% CI: 92-100%)
92% (95% CI: 89-93%)
1,113,661(Male 65-74)
1,168,074(Female 65-74)
576,829 (Male 75-84)
658,438 (Female 75-84)
OAC: 74%
Antiplatelet (alone) / no
treatment: 26%
OAC: 82%
Antiplatelet (alone)/no
treatment: 15%
Warfarin: 10%
NOACs: 90%
34%
$20

Lowres et al, 201420
June 2019

Apportioned using a
mean cost for NOACs
Includes cost of eHealth
tools and GP/nurse time
(5min)
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0.85 per unclassified
result
0.15 for each 12 lead ECG

GP visit (follow-up)
Annual medication costs
Warfarin

$38.20

Apixaban

$1119.72 per year

Warfarin 1mg + 3mg
(once per day)
2 tablets per day

Dabigatran

$1065.24 per year

2 tablets per day

Rivaroxaban

$1050.72 per year

1 tablet per day

$238.83 per year

Annual cost of monitoring/consults for those on OAC:
Warfarin:
$824.95 TOTAL
$150.35 per year
• GP visits

Specialist consult
INR monitoring

NOACs:
• GP visits

•

Pathology

$155.60 per year
$519 per year
$303.15 TOTAL
$112.15 per year

$35.40 per year

Australian Bureau of Statistics,
201933

AF-SMART rural results section
[baseline data]

Discount rate
5%
Follow-up costs for those with abnormal screening result [possible AF or unclassified]
12 lead ECG
$31.75
1 per possible AF result

•
•

Source
Lowres et al, 201332

3 GP visits per year (1
initial, 2 follow up)
1 visit per year
30 INR tests per year

AF-SMART rural results section
[screen-detected AF during
study]
AF-SMART rural results [not
published]
AF-SMART rural results section
Based on the cost of recording
a 12-lead ECG without
interpretation (MBS item
1170234)

MBS item 1170034

MBS item 2334
PBS dispensed price for
maximum quantity35
PBS dispensed price for
maximum quantity35
PBS dispensed price for
maximum quantity35
PBS dispensed price for
maximum quantity35

MBS item 3634 = $73.95 (initial)
MBS item 2334 = $38.20 (follow
up)
MBS item 11034
MBS item 6512034, $17.30 per
test

2 GP visits per year (1
initial, 1 follow-up)

MBS item 3634 = $73.95 (initial)
MBS item 2334 = $38.20 (follow
up)

2 per year

MBS item 6651234

Item

•

Cost/measure

Specialist consult

$155.60 per year

Details
(liver function, urea,
electrolytes, creatinine
tests)
1 visit per year for all
patients on OAC

Source
$17.70 per test

MBS item 11034
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Other costs for those with diagnosed AF
Echocardiogram
$230.65
Once per patient
MBS item 5511334
Stroke data
Hospitalisation ischemic stroke
$71,814 (first stroke)
Includes hospitalisation,
Cadilhac et al, 200736 updated
$35,215 (recurrent
rehabilitation and other
to 2019 prices using Australian
stroke)
ongoing medical costs
Health Price Deflator Index
QALYs per ischaemic stroke
5.09
Cadilhac et al, 201021
Annual incidences of stroke and all-cause mortality by age and sex
Martinez et al, 201437
Bleeding costs
Crude excess incidence rate per
Martinez et al, 201437
1,000 person-years of major bleeds
for those aged 65 – 74 years
4.8 (95% CI: 2.2-7.4)
Crude excess incidence rate per
Martinez et al 201437
1,000 person-years of major bleeds
for those aged 75 – 84 years
4.2 (95% CI: 1.3-7.2)
Cost of a major gastrointestinal
Australian Refined Diagnosis
bleed
$6,772
Related Groups (AR DRG)38
Cost of a major intracranial bleed
$22,255
AR DRG38
Proportion of major bleeds:
- gastrointestinal
85%
- intracranial
15%
AF, atrial fibrillation; iECG, smartphone electrocardiogram; OAC, oral anticoagulant; NOAC, novel oral
anticoagulant; GP, general practitioner; ECG, electrocardiogram; PBS, pharmaceutical benefits scheme; MBS,
medical benefits schedule; INR, international normalised ratio; QALYs, quality adjusted life years; $ = AU$, CI,
confidence interval

The full model is available on request from the corresponding author.

